Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells

High mortality in pancreatic cancer patients is partly due to resistance to chemotherapy. We describe that human pancreatic cancer cells acquire drug resistance by a novel mechanism in which they expel and remove chemotherapeutic drugs from the microenvironment via microvesicles (MVs). Using human pancreatic cancer cells that exhibit varied sensitivity to gemcitabine (GEM), we show that GEM exposure triggers the cancer cells to release MVs in an amount that correlates with that cell line's sensitivity to GEM. The importance of MV-release in gaining drug resistance in GEM-resistant pancreatic cancer cells was confirmed when the inhibition of MV-release sensitized the cells to GEM treatment, both in vitro and in vivo. Mechanistically, MVs remove drugs that are internalized into the cells and that are in the microenvironment. The differences between the drug-resistant and drug-sensitive pancreatic cancer cell lines tested here are explained based on the variable content of influx/efflux proteins present on MVs, which directly dictates the ability of MVs either to trap GEM or to allow GEM to flow back to the microenvironment.

[1]  Jian Jin,et al.  Tumor endothelial expression of P-glycoprotein upon microvesicular transfer of TrpC5 derived from adriamycin-resistant breast cancer cells. , 2014, Biochemical and biophysical research communications.

[2]  T. Hagemann,et al.  The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1) , 2015, Clinical Cancer Research.

[3]  T. Roberts,et al.  DEF-1/ASAP1 Is a GTPase-activating Protein (GAP) for ARF1 That Enhances Cell Motility through a GAP-dependent Mechanism* , 2002, The Journal of Biological Chemistry.

[4]  Paul D. Martin,et al.  AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.

[5]  J. Meldolesi,et al.  Ectosomes and exosomes: shedding the confusion between extracellular vesicles. , 2015, Trends in cell biology.

[6]  K. Al-Nedawi.  The Yin–Yang of Microvesicles (Exosomes) in Cancer Biology , 2014, Front. Oncol..

[7]  G. Grau,et al.  Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells , 2009, Leukemia.

[8]  I. Vorobjev,et al.  Circulating microparticles: square the circle , 2013, BMC Cell Biology.

[9]  Matt Trau,et al.  A comparative study of submicron particle sizing platforms: accuracy, precision and resolution analysis of polydisperse particle size distributions. , 2013, Journal of colloid and interface science.

[10]  M. Taguchi,et al.  Membrane transport mechanisms of quinidine and procainamide in renal LLC-PK1 and intestinal LS180 cells. , 2010, Biological & pharmaceutical bulletin.

[11]  Yuan Zhang,et al.  Extracellular vesicles in breast cancer drug resistance and their clinical application , 2016, Tumor Biology.

[12]  A. Molinari,et al.  Microenvironmental pH Is a Key Factor for Exosome Traffic in Tumor Cells* , 2009, The Journal of Biological Chemistry.

[13]  M. Berger,et al.  Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma , 2013, Clinical Cancer Research.

[14]  Valentina R Minciacchi,et al.  Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. , 2015, Seminars in cell & developmental biology.

[15]  L. Buscail,et al.  Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. , 2016, European journal of cancer.

[16]  Denise G. Lanza,et al.  Tumor-derived mesenchymal stem cells and orthotopic site increase the tumor initiation potential of putative mouse mammary cancer stem cells derived from MMTV-PyMT mice , 2012, Tumor Biology.

[17]  C. Théry,et al.  Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. , 2014, Annual review of cell and developmental biology.

[18]  James W. Clancy,et al.  Tumor‐derived microvesicles in the tumor microenvironment: How vesicle heterogeneity can shape the future of a rapidly expanding field , 2015, BioEssays : news and reviews in molecular, cellular and developmental biology.

[19]  E. Raymond,et al.  Targeting the Ras–ERK pathway in pancreatic adenocarcinoma , 2012, Cancer and Metastasis Reviews.

[20]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.

[21]  F. Petrucci,et al.  Exosome Release and Low pH Belong to a Framework of Resistance of Human Melanoma Cells to Cisplatin , 2014, PloS one.

[22]  Valentina R Minciacchi,et al.  Focus on Extracellular Vesicles: New Frontiers of Cell-to-Cell Communication in Cancer , 2016, International journal of molecular sciences.

[23]  Huamin Wang,et al.  Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.

[24]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[25]  Graca Raposo,et al.  ARF6-Regulated Shedding of Tumor Cell-Derived Plasma Membrane Microvesicles , 2009, Current Biology.

[26]  M. Reni,et al.  Target therapies in pancreatic carcinoma. , 2014, Current medicinal chemistry.

[27]  J. Lötvall,et al.  Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes , 2013, Journal of extracellular vesicles.

[28]  Jacopo Meldolesi,et al.  Shedding microvesicles: artefacts no more. , 2009, Trends in cell biology.

[29]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[30]  Xi Yang,et al.  The Role of Extracellular Vesicles: An Epigenetic View of the Cancer Microenvironment , 2015, BioMed research international.

[31]  Y. Akao,et al.  Extracellular Disposal of Tumor-Suppressor miRs-145 and -34a via Microvesicles and 5-FU Resistance of Human Colon Cancer Cells , 2014, International journal of molecular sciences.

[32]  M. Boroujerdi,et al.  Time and concentration dependency of P-gp, MRP1 and MRP5 induction in response to gemcitabine uptake in Capan-2 pancreatic cancer cells , 2015, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  Silvia Maria Doglia,et al.  Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[34]  R W Wilkinson,et al.  The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models , 2012, British Journal of Cancer.

[35]  James W. Clancy,et al.  ADP-ribosylation factor 6 regulates tumorigenic and invasive properties in vivo. , 2009, Cancer research.

[36]  L. O’Driscoll,et al.  ISEV position paper: extracellular vesicle RNA analysis and bioinformatics , 2013, Journal of extracellular vesicles.

[37]  Chunrong Yu,et al.  BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. , 2008, Cancer research.

[38]  I. Nakano,et al.  Extracellular vesicles in the biology of brain tumour stem cells--Implications for inter-cellular communication, therapy and biomarker development. , 2015, Seminars in cell & developmental biology.

[39]  Penelope V Dalla,et al.  Breast Cancer-Derived Microparticles Display Tissue Selectivity in the Transfer of Resistance Proteins to Cells , 2013, PloS one.